Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma

Jeanny B. Aragon-Ching, MD, FACP, clinical program director, Genitourinary Cancers, the Inova Schar Cancer Institute, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 (NCT02603432) trial in urothelial carcinoma. 

The JAVELIN Bladder 100 trial evaluated avelumab (Bavencio) maintenance plus best supportive care vs best supportive care alone in patients with locally advanced or metastatic urothelial carcinoma who did not progress following first-line, platinum-based chemotherapy.

Findings from the trial catapulted maintenance avelumab into the standard of care of first-line urothelial carcinoma for patients who fit the eligibility criteria of the trial, Aragon-Ching says. Chemotherapy remains the optimal frontline treatment option for these patients, Aragon-Ching adds, noting that patients can receive gemcitabine plus cisplatin, or gemcitabine plus carboplatin if they are ineligible for cisplatin, Aragon-Ching explains.

Patients who achieve a response or stable disease following chemotherapy can advance to maintenance avelumab, and this remains the standard of care, Aragon-Ching continues. Benefits have continued to be observed in patients who receive prolonged avelumab maintenance, Aragon-Ching concludes.